Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies

Br J Haematol. 2018 Mar;180(5):735-737. doi: 10.1111/bjh.14427. Epub 2016 Dec 15.

Thomas Prebet^{1

2}, Jacques Delaunay³, Eric Wattel⁴, Thorsten Braun^{5

6}, Pascale Cony-Makhoul⁷, Sophie Dimicoli⁸, Stephan Wickenhauser⁹, Julie Lejeune^{6

10}, Sylvie Chevret^{6

10}, Fatiha Chermat^{6

11}, Pierre Fenaux^{6

11}, Norbert Vey¹; Groupe Francophone des Myélodysplasies

¹ Haematology Department, Institut PAOLI-CALMETTES and Aix-Marseille Université, Marseille, France.
² Section of Hematology, Department of Internal Medicine, Yale University, New Haven, CT, USA.
³ Haematology Department, Centre Hospitalo universitaire, Nantes, France.
⁴ Haematology Department, Hôpital Lyon Sud, Pierre-Bénite, France.
⁵ Haematology Department, Hôpital Avicenne, Bobigny, France.
⁶ Assistance Publique Hopitaux de Paris (AP-HP), Paris, France.
⁷ Haematology Department, Centre Hospitalier Annecy, Pringy, France.
⁸ Haematology Department, Centre Hospitalo Unversitaire Tripode, Pessac, France.
⁹ Haematology Department, Centre Hospitalo universitaire, Nimes, France.
¹⁰ Biostatistic Department, Hôpital Saint Louis, Paris, France.
¹¹ Haematology Department, Hôpital Saint Louis, Paris, France.

No abstract available

Keywords: epigenetic; myelodysplasia; myeloid leukaemia; relapse.

Publication types